Breyanzi (lisocabtagene maraleucel), new Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma
The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene…
FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma
Kite, a Gilead Company has announced that the U.S. Food and Drug Administration…